Double Blind Randomized Controlled, H1 Coil In Subjects With Bipolar Depression
Primary Purpose
Bipolar Depression
Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
H-Coil deep TMS
sham
Sponsored by
About this trial
This is an interventional treatment trial for Bipolar Depression focused on measuring bipolar, depression, prefrontal, cortex, antidepressant, response
Eligibility Criteria
Inclusion Criteria:• Outpatients
- Diagnosed by two senior psychiatrists as suffering from bipolar depression (BP1, BP2) episode according to DSM IV using the Structured Clinical Interview for DSM-4 (SCID), with additional requirement of duration for the current episode ≥ 4 weeks and CGI ≥ 4.
- Rating on HAM-D (17 items) >20 and item 1 ≥2 at the screening visit.
- Age: 18-65 years.
- Gave informed consent for participation in the study.
- Negative answers on safety screening questionnaire for transcranial magnetic stimulation
- Taking mood stabilizing medication (e.g., lithium) on an acceptable range of dosage according to recent blood examination or antipsychotic medication as mood stabilizers prescribed by their treating physician
- According to the treating physician the patient is compliant in taking the mood-stabilizing medication.
- Medication resistance to at least two different antidepressant treatments, defined as resistance to a minimum of 2 antidepressant drug trials of adequate dose and duration in the current episode or previous episodes defined as a minimum level of 3 on the ATHF per antidepressant drug-trial.
- Patients who have not completed antidepressant trials of adequate dose and duration due to intolerance to therapy may be included if they have demonstrated intolerance to 3 or more anti-depressant medications in the current or a previous episodes.
- If currently taking antidepressant pharmacotherapy, must be clinically appropriate to discontinue treatment with those agents.
- Able to tolerate psychotropic medication washout and no psychotropics during the H-coil deep brain rTMS other than benzodiazepine at equivalent dose of up to 3 mg lorazepam every day.
- Right hand dominance.
Exclusion Criteria:• Diagnosis as suffering from other diagnosis on axis 1 (like: schizophrenia, geriatric depression).
- Diagnosis as suffering from Severe Borderline Personality Disorder or hospitalized due to exacerbation related to of borderline personality disorder.
- Substantial suicidal risk as judged by the treating psychiatrist.
- Attempted suicide in the past year.
- Patients with a bipolar cycle of less than 30 days.
- History of epilepsy or seizure in first degree relatives.
- History of head injury.
- History of any metal in the head (outside the mouth).
- Known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps.
- History of frequent or severe headaches.
- History of migraine.
- History of hearing loss.
- Known history of cochlear implants
- History of substance abuse within the past 6 months (except nicotine and caffeine) or alcoholism
- Pregnancy or not using a reliable method of birth control.
- Unstable Systemic and metabolic disorders.
- Unstable neurological or medical disease
- Inadequate communication with the patient.
- Under custodial care.
- Participation in current clinical study or clinical study within 30 days prior to this study.
Sites / Locations
- shalvataMHCRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
1
2
Arm Description
Deep TMS treatment
inactive stimulation
Outcomes
Primary Outcome Measures
change in the Hamilton depression rating scale score
Secondary Outcome Measures
Clinical antidepressant remission at the end of the treatment, defined as exit Hamilton Depression Rating Scale <10.
Full Information
NCT ID
NCT00657735
First Posted
April 8, 2008
Last Updated
January 4, 2012
Sponsor
Shalvata Mental Health Center
Collaborators
Brainsway
1. Study Identification
Unique Protocol Identification Number
NCT00657735
Brief Title
Double Blind Randomized Controlled, H1 Coil In Subjects With Bipolar Depression
Official Title
A Prospective Double Blind Randomized Controlled Trial To Explore The Tolerability, Safety And Efficacy Of The H1-Coil Deep Transcranial Magnetic Stimulation (TMS) In Subjects With Bipolar Depression
Study Type
Interventional
2. Study Status
Record Verification Date
January 2012
Overall Recruitment Status
Unknown status
Study Start Date
January 2009 (undefined)
Primary Completion Date
January 2013 (Anticipated)
Study Completion Date
January 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shalvata Mental Health Center
Collaborators
Brainsway
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the study is to explore the efficacy and safety of H1-Coil deep brain rTMS in subjects with bipolar depression , currently treated with mood stabilizer and previously unsuccessfully treated with antidepressant medications
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Depression
Keywords
bipolar, depression, prefrontal, cortex, antidepressant, response
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Deep TMS treatment
Arm Title
2
Arm Type
Sham Comparator
Arm Description
inactive stimulation
Intervention Type
Device
Intervention Name(s)
H-Coil deep TMS
Other Intervention Name(s)
H1 coil dTMS
Intervention Description
20 daily deep rTMS treatments
Intervention Type
Device
Intervention Name(s)
sham
Intervention Description
inactive treatment
Primary Outcome Measure Information:
Title
change in the Hamilton depression rating scale score
Time Frame
7 weeks
Secondary Outcome Measure Information:
Title
Clinical antidepressant remission at the end of the treatment, defined as exit Hamilton Depression Rating Scale <10.
Time Frame
7 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
68 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:• Outpatients
Diagnosed by two senior psychiatrists as suffering from bipolar depression (BP1, BP2) episode according to DSM IV using the Structured Clinical Interview for DSM-4 (SCID), with additional requirement of duration for the current episode ≥ 4 weeks and CGI ≥ 4.
Rating on HAM-D (17 items) >20 and item 1 ≥2 at the screening visit.
Age: 18-65 years.
Gave informed consent for participation in the study.
Negative answers on safety screening questionnaire for transcranial magnetic stimulation
Taking mood stabilizing medication (e.g., lithium) on an acceptable range of dosage according to recent blood examination or antipsychotic medication as mood stabilizers prescribed by their treating physician
According to the treating physician the patient is compliant in taking the mood-stabilizing medication.
Medication resistance to at least two different antidepressant treatments, defined as resistance to a minimum of 2 antidepressant drug trials of adequate dose and duration in the current episode or previous episodes defined as a minimum level of 3 on the ATHF per antidepressant drug-trial.
Patients who have not completed antidepressant trials of adequate dose and duration due to intolerance to therapy may be included if they have demonstrated intolerance to 3 or more anti-depressant medications in the current or a previous episodes.
If currently taking antidepressant pharmacotherapy, must be clinically appropriate to discontinue treatment with those agents.
Able to tolerate psychotropic medication washout and no psychotropics during the H-coil deep brain rTMS other than benzodiazepine at equivalent dose of up to 3 mg lorazepam every day.
Right hand dominance.
Exclusion Criteria:• Diagnosis as suffering from other diagnosis on axis 1 (like: schizophrenia, geriatric depression).
Diagnosis as suffering from Severe Borderline Personality Disorder or hospitalized due to exacerbation related to of borderline personality disorder.
Substantial suicidal risk as judged by the treating psychiatrist.
Attempted suicide in the past year.
Patients with a bipolar cycle of less than 30 days.
History of epilepsy or seizure in first degree relatives.
History of head injury.
History of any metal in the head (outside the mouth).
Known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps.
History of frequent or severe headaches.
History of migraine.
History of hearing loss.
Known history of cochlear implants
History of substance abuse within the past 6 months (except nicotine and caffeine) or alcoholism
Pregnancy or not using a reliable method of birth control.
Unstable Systemic and metabolic disorders.
Unstable neurological or medical disease
Inadequate communication with the patient.
Under custodial care.
Participation in current clinical study or clinical study within 30 days prior to this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yechiel Levkovitz, MD
Email
ylevk@clalit.org.il
First Name & Middle Initial & Last Name or Official Title & Degree
Oded Meiron, PhD student
Email
odedmei@clalit.org.il
Facility Information:
Facility Name
shalvataMHC
City
Hod Hasharon
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eiran v Harel, MD
12. IPD Sharing Statement
Learn more about this trial
Double Blind Randomized Controlled, H1 Coil In Subjects With Bipolar Depression
We'll reach out to this number within 24 hrs